Novartis AG (NVS): Price and Financial Metrics

Novartis AG (NVS)

Today's Latest Price: $92.90 USD

3.04 (-3.17%)

Updated Jan 27 4:00pm

Add NVS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVS Stock Summary

  • NVS has a market capitalization of $217,304,914,339 -- more than approximately 99.39% of US stocks.
  • In terms of volatility of its share price, NVS is more volatile than merely 1.15% of stocks we're observing.
  • Novartis Ag's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 7.79%, greater than the shareholder yield of 80.14% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Novartis Ag, a group of peers worth examining would be PFE, MRK, LLY, ABT, and T.
  • NVS's SEC filings can be seen here. And to visit Novartis Ag's official web site, go to

NVS Stock Price Chart Interactive Chart >

Price chart for NVS

NVS Price/Volume Stats

Current price $92.90 52-week high $99.84
Prev. close $95.94 52-week low $69.18
Day low $92.86 Volume 5,090,479
Day high $94.87 Avg. volume 2,271,571
50-day MA $91.71 Dividend yield 2.1%
200-day MA $87.59 Market Cap 212.62B

Novartis AG (NVS) Company Bio

Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$92.90$64.51 -33%

Below please find a table outlining a discounted cash flow forecast for NVS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novartis Ag ranked in the 42th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 32.33%. The most interesting components of our discounted cash flow analysis for Novartis Ag ended up being:

  • NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 29.51% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 8. This value is greater than merely 24.31% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Novartis Ag? See AMGN, QDEL, STE, MEDP, and USPH.

NVS Latest News Stream

Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream

Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Novartis AG (NVS) CEO Vas Narasimhan on Q4 2020 Results - Earnings Call Transcript

Novartis AG (NVS) Q4 2020 Earnings Conference Call January 26, 2021 08:00 ET Company Participants Samir Shah - Investor Relations Vas Narasimhan - Chief Executive Officer Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology Harry Kirsch - Chief Financial Officer John Tsai - Head, Global Drug...

SA Transcripts on Seeking Alpha | January 26, 2021

Novartis EPS misses by $0.05, misses on revenue

Novartis (NVS): Q4 Non-GAAP EPS of $1.34 misses by $0.05; GAAP EPS of $0.92 misses by $0.39.Revenue of $12.77B (+3.0% Y/Y) misses by $100M.Core operating profit of $3.5B vs. estimate of $3.63B.Core operating income margin was 27.4% compared to estimate of 28.4%.2021 Outlook: Net Sales expected to grow low to mid...

Seeking Alpha | January 26, 2021

Novartis Slammed: Expects Covid To Impact Drug Sales Until Mid-2021

Novartis stock toppled Tuesday after the drug company said it expects the coronavirus pandemic to weigh on prescription sales until mid-2021. Shares remained above a buy point, however.

Yahoo | January 26, 2021

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Antares Pharma Inc (NASDAQ: ATRS) Applied Molecular Transport Inc. (NASDAQ: AMTI) argenx SE – ADR (NASDAQ: ARGX) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX) Beigene Ltd (NASDAQ: BGNE) BioNano Genomics Inc (NASDAQ: BNGO) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA) ChemoCentryx Inc (NASDAQ: CCXI) Clearpoint Neuro Inc (NASDAQ: CLPT) DarioHealth Corp (NASDAQ: DRIO) DermTech Inc (NASDAQ...

Yahoo | January 26, 2021

Novartis Gives Cautious Outlook and Warns Covid-19 Impact Will Last Until Mid 2021. The Stock Is Falling.

(NOVN) stock slipped 2.4% in early trading on Tuesday, as the Swiss pharmaceutical company offered cautious guidance and said the Covid-19 pandemic would continue to affect sales through the first half of 2021. Net sales in the fourth quarter rose 1% to $12.77 billion, below the FactSet consensus of $12.9 billion, as the company said Covid-19 lockdowns continued to negatively impact sales, most notably in dermatology and ophthalmology, while its Sandoz retail business has also been affected during the year. Fourth-quarter net profit grew 93% to $2.1 billion but also missed estimates of $2.66 billion, while core operating income rose 2% to $3.5 billion.

Yahoo | January 26, 2021

Read More 'NVS' Stories Here

NVS Price Returns

1-mo 1.86%
3-mo 19.00%
6-mo 13.10%
1-year -0.46%
3-year 21.79%
5-year 56.15%
YTD -1.62%
2020 2.08%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8786 seconds.